Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and PPI Effect of Acalabrutinib NG Suspension
NCT04435483Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- May 2020
- Primary completion
- Jun 2020
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of acalabrutinib tablet (Variant 1) in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) (2 arms), sponsored by AstraZeneca. Primary endpoints: Area under plasma concentration-time curve from time zero to infinity at Day 2, Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration at Day 2 and 1 more. Started May 2020; status: completed.
02
Drugs
acalabrutinib tablet (Variant 1)
03
Conditions
chronic lymphocytic leukemia (CLL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT04435483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04435483.